Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Conditions

• Obesity
• Overweight

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• ABBV-295 — DRUG
  Subcutaneous
• Placebo — DRUG
  Subcutaneous

Study Details

Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight with weight-related comorbidities. ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management. Participants are placed into multiple treatment groups with different dosing paradigms of ABBV-295 or placebo. Participants will not know which treatment they are receiving, and there is a chance of being assigned to placebo. Adults with obesity or overweight (as defined by BMI) with weight-related comorbidities will be enrolled. Approximately 360 participants will be enrolled in the study at approximately 70 sites in the United States and Puerto Rico. Participants will receive subcutaneous (SC) injections of ABBV-295 solution for injection or matching placebo administered via pre-filled syringes for 52 weeks during the Double-Blind Period. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Key Dates

First listed

Aug 7, 2026

Start date

Aug 4, 2026

Status verified

Aug 2026

Primary completion

Mar 31, 2028

Completion

Mar 31, 2028

Study Design

Enrollment

360 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: ABBV-295 Arm 1
  Particpants will have their doses escalated up to a maintenance dose during the Double-Blind Period.
• Experimental: ABBV-295 Arm 2
  Participants will have their doses escalated up to a maintenance dose during the Double-Blind Period.
• Experimental: ABBV-295 Arm 3
  Participants will have their doses escalated up to a maintenance dose during the Double-Blind Period.
• Experimental: ABBV-295 Arm 4
  Particpants will have their doses escalated up to a maintenance dose during the Double-Blind Period.
• Experimental: ABBV-295 Arm 5
  Participants will have their doses escalated up to a maintenance dose during the Double-Blind Period.
• Experimental: ABBV-295 Arm 6
  Particpants will have their doses escalated up to a maintenance dose during the Double-Blind Period.
• Placebo Comparator: Placebo
  Participants will follow the same dosing schedule as active treatment arms during the Double-Blind Period.

Primary Outcome Measure

Percent Change From Baseline in Body Weight [ Time Frame: Baseline (Week 0) to Week 32 ]

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Locations (33)

Find similar trials in Scottsdale, AZ

Related Studies

• Investigating the Impact of Obesity on Pubertal Development in Girls
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
• Metabolic Effects of Angiotensin-(1-7)
  PHASE1 · Recruiting · Vanderbilt University · Nashville, Tennessee
• Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
  Not Yet Recruiting · Keith Pereira, MD: · St Louis, Missouri
• Inflammation, Diabetes, Ethnicity and Obesity Cohort
  Recruiting · University of California, San Francisco · San Francisco, California